{"id":"methylphenidate-ritalin","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Insomnia"},{"rate":"15-25","effect":"Decreased appetite"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Nervousness or anxiety"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Elevated blood pressure"},{"rate":"5-10","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL796","moleculeType":"Small molecule","molecularWeight":"233.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control in patients with attention deficit hyperactivity disorder (ADHD) and narcolepsy.","oneSentence":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:47.831Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT05842330","phase":"PHASE3","title":"Benefits of ADHD Treatment in Detained People","status":"RECRUITING","sponsor":"Stéphanie Baggio","startDate":"2024-01-01","conditions":"ADHD","enrollment":150},{"nctId":"NCT06906328","phase":"NA","title":"MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-12-11","conditions":"ADHD-add","enrollment":248},{"nctId":"NCT05721235","phase":"PHASE4","title":"A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD","status":"COMPLETED","sponsor":"Corium, Inc.","startDate":"2023-06-02","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":123},{"nctId":"NCT05536011","phase":"","title":"WAKIX® (Pitolisant) Pregnancy Registry","status":"RECRUITING","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2021-08-24","conditions":"Pregnancy Related, Narcolepsy","enrollment":1329},{"nctId":"NCT05685732","phase":"PHASE4","title":"An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD","status":"COMPLETED","sponsor":"Corium, Inc.","startDate":"2023-03-22","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":246},{"nctId":"NCT00829673","phase":"PHASE1","title":"Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT00829712","phase":"PHASE1","title":"Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT04603391","phase":"PHASE4","title":"Cannabidiol and CES1 Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-02-25","conditions":"Drug Interaction","enrollment":14},{"nctId":"NCT04384562","phase":"NA","title":"Studying the Role of Brain Molecules for Decision Making","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2020-12-17","conditions":"Decision Making, Healthy","enrollment":160},{"nctId":"NCT04741516","phase":"PHASE4","title":"Evaluation of the Effect Foquest® on Sleep in Children Aged 6-12 With ADHD","status":"UNKNOWN","sponsor":"JPM van Stralen Medicine Professional","startDate":"2020-12-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":41},{"nctId":"NCT04987762","phase":"PHASE4","title":"Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2021-08-03","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":103},{"nctId":"NCT02683265","phase":"PHASE4","title":"A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-04-25","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":158},{"nctId":"NCT04964427","phase":"NA","title":"The Effects of Methylphenidate and Non-invasive Brain Stimulation on Inhibitory Control in Children With ADHD","status":"COMPLETED","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2021-02-08","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":26},{"nctId":"NCT04178993","phase":"PHASE1","title":"Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]","status":"COMPLETED","sponsor":"Craig Rush","startDate":"2019-09-01","conditions":"Methamphetamine Use Disorder","enrollment":8},{"nctId":"NCT01269463","phase":"PHASE3","title":"Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2011-01-19","conditions":"Attention Deficit Hyperactivity Disorder, ADHD","enrollment":26},{"nctId":"NCT02704390","phase":"PHASE3","title":"Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2016-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":64},{"nctId":"NCT02450890","phase":"PHASE3","title":"Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2015-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":114},{"nctId":"NCT02470234","phase":"PHASE4","title":"Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":10},{"nctId":"NCT04152629","phase":"PHASE4","title":"Real World Evidence of the Efficacy and Safety of FOQUEST","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2019-09-19","conditions":"Attention Deficit-Hyperactivity Disorder","enrollment":257},{"nctId":"NCT00763971","phase":"PHASE3","title":"Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2008-11-17","conditions":"ADHD","enrollment":336},{"nctId":"NCT01552902","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-03","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":549},{"nctId":"NCT01552915","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-17","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":464},{"nctId":"NCT02700685","phase":"PHASE3","title":"Effect of Pycnogenol® on ADHD","status":"COMPLETED","sponsor":"Nina Hermans","startDate":"2017-09-01","conditions":"ADHD","enrollment":88},{"nctId":"NCT02954679","phase":"","title":"French Study on COgnitive Enhancement and Consumption of Psychoactive Substances Among Youth Students","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-01-23","conditions":"Psychoactive Substances Consumption, Substance-related Disorder, Off Label-use","enrollment":30000},{"nctId":"NCT01933217","phase":"PHASE4","title":"Methylphenidate for Attention Problems After Pediatric TBI","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2013-11","conditions":"Traumatic Brain Injury, TBI, ADHD","enrollment":26},{"nctId":"NCT04371146","phase":"NA","title":"The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2019-07-03","conditions":"Healthy","enrollment":120},{"nctId":"NCT02021214","phase":"EARLY_PHASE1","title":"Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-03","conditions":"PTSD","enrollment":24},{"nctId":"NCT02430896","phase":"","title":"Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2015-02","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":600},{"nctId":"NCT03519022","phase":"EARLY_PHASE1","title":"Behavioral Effects of Drugs: Inpatient (35)","status":"COMPLETED","sponsor":"Craig Rush","startDate":"2018-06-01","conditions":"Cocaine Use Disorder","enrollment":9},{"nctId":"NCT01853280","phase":"PHASE2, PHASE3","title":"L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":47},{"nctId":"NCT02677519","phase":"PHASE4","title":"A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD","status":"UNKNOWN","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":120},{"nctId":"NCT02704546","phase":"NA","title":"Methylphenidate (Ritalin®) Effect During Exposure to Exercise and Heat Stress in ADD/ADHD Treated Patients","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2016-04","conditions":"Methylphenidate","enrollment":20},{"nctId":"NCT00302458","phase":"PHASE4","title":"A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT00475735","phase":"PHASE2","title":"A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":72},{"nctId":"NCT00151970","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2005-06","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":128},{"nctId":"NCT00444574","phase":"PHASE3","title":"Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2004-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":282},{"nctId":"NCT01377662","phase":"PHASE2","title":"PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)","status":"COMPLETED","sponsor":"Tong Lee","startDate":"2011-08","conditions":"Methamphetamine Dependence, Cocaine Dependence","enrollment":30},{"nctId":"NCT01228604","phase":"PHASE4","title":"Cost-Effectiveness Study Of The Treatment Of Attention Deficit/Hyperactivity Disorder In Brazil","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2010-12","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":23},{"nctId":"NCT00852059","phase":"PHASE4","title":"Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA)","status":"TERMINATED","sponsor":"Prof. Huss","startDate":"2009-03","conditions":"ADHD","enrollment":32},{"nctId":"NCT00069927","phase":"PHASE2","title":"Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2003-08","conditions":"Depression, Neurotoxicity, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":12},{"nctId":"NCT00302393","phase":"PHASE3","title":"Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-06","conditions":"Healthy","enrollment":20},{"nctId":"NCT00937040","phase":"PHASE4","title":"Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2009-07","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":357},{"nctId":"NCT00564954","phase":"PHASE4","title":"A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":86},{"nctId":"NCT00269815","phase":"PHASE3","title":"Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00269802","phase":"PHASE3","title":"A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00269789","phase":"PHASE3","title":"A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1998-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00776009","phase":"PHASE4","title":"Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":165},{"nctId":"NCT00304681","phase":"PHASE3","title":"An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":147},{"nctId":"NCT00246233","phase":"PHASE3","title":"CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2005-06","conditions":"Depressive Disorder, Major","enrollment":145},{"nctId":"NCT00249353","phase":"PHASE3","title":"An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","startDate":"2002-03","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":274,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"methylphenidate (Ritalin®)","genericName":"methylphenidate (Ritalin®)","companyName":"Hospital de Clinicas de Porto Alegre","companyId":"hospital-de-clinicas-de-porto-alegre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}